Finally, our estimation about OS did not manifest in statistical significance (P > 0.10).14 All above pooled results proved that palbociclib had high clinical value in the treatment for ER‐positive and HER2‐negative breast cancer, but the therapeutic value of palbociclib in other tumors is unclear. Here, ERBB2 is linked to breast carcinoma.